Cell therapy is coming into its own as an effective therapeutic avenue for cancer. Into that fray in November 2019 launched Umoja Biopharma, whose unique immunotherapy approach aims to re-engineer a patient’s own immune system in vivo to attack and destroy hematologic and solid organ-based tumors.